KRAS and neoplasm: Reversing this process by targeting the oncogenic miRNAs (miR-25-3p and/or miR-15a-5p) and modulating the ratio between the tumor-suppressor miRNA (miR-18a-3p) and its downstream target (KRAS) has direct effect on proliferation and survival.